Skip to main content
Premium Trial:

Request an Annual Quote

Noridian Providing Limited Coverage for MDx Tests as Predictive Classifiers for NSCLC

NEW YORK – Medicare Administrative Contractor Noridian Health Solutions recently issued a final local coverage determination aligning its coverage with Palmetto's earlier decision to cover molecular diagnostic laboratory tests as predictive classifiers for non-small cell lung cancer.

Tests are considered reasonable and necessary if a patient has a non-squamous NSCLC with a tumor size of less than five centimeters and no positive lymph nodes. The patient must also be healthy enough to tolerate chemotherapy and adjuvant platinum-containing chemotherapy must be under consideration as treatment for the patient. The test must also be ordered by a clinician treating the patient for NSCLC to help decide whether to recommend adjuvant chemotherapy.

Their determination was based on studies of Razor Genomics' 14-gene lung cancer assay. Oncocyte acquired Razor Genomics last year and named the test DetermaRx.  

Noridian said that evidence shows molecular risk stratification with the Razor assay "enhances risk stratification among patients with tumors considered low risk," and noted it could accurately predict patients who will have disease recurrence or metastatic disease.

The LCD goes into effect Aug. 24. Last month, CGS Administrators also aligned its coverage with Palmetto's decision. 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.